Hossein Jadvar

List of Publications by Year
in descending order

141 papers	5,154 citations	101543 36 h-index	95266 68 g-index
145 all docs	145 docs citations	145 times ranked	5881 citing authors

#	Article	IF	Citations
1	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology, The, 2019, 20, 1286-1294.	10.7	338
2	Prostate Cancer: PET with ¹⁸F-FDG, ¹⁸F- or ¹¹C-Acetate, and ¹⁸F- or ¹¹C-Choline. Journal of Nuclear Medicine, 2011, 52, 81-89.	5.0	288
3	The SNMMI Practice Guideline for Therapy of Thyroid Disease with ¹³¹I 3.0. Journal of Nuclear Medicine, 2012, 53, 1633-1651.	5.0	229
4	¹⁸F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization. Journal of Nuclear Medicine, 2009, 50, 1820-1827.	5.0	203
5	Incidental Colonic Fluorodeoxyglucose Uptake: Correlation with Colonoscopic and Histopathologic Findings. Radiology, 2002, 224, 783-787.	7.3	187
6	A systematic review on diagnostic accuracy of CT-based detection of significant coronary artery disease. European Journal of Radiology, 2008, 65, 449-461.	2.6	156
7	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	10.7	153
8	PSMA Theranostics: Current Status and Future Directions. Molecular Imaging, 2018, 17, 153601211877606.	1.4	150
9	Competitive advantage of PET/MRI. European Journal of Radiology, 2014, 83, 84-94.	2.6	149
10	Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 5-10.	6.4	137
11	Is There Use for FDG-PET in Prostate Cancer?. Seminars in Nuclear Medicine, 2016, 46, 502-506.	4.6	128
12	Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2012, 37, 637-643.	1.3	125
13	PET and PET/CT in Pediatric Oncology. Seminars in Nuclear Medicine, 2007, 37, 316-331.	4.6	115
14	Baseline ¹⁸F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine, 2013, 54, 1195-1201.	5.0	110
15	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1963-1996.	1.6	107
16	Molecular Imaging of Prostate Cancer: PET Radiotracers. American Journal of Roentgenology, 2012, 199, 278-291.	2.2	95
17	Radiotheranostics in Cancer Diagnosis and Management. Radiology, 2018, 286, 388-400.	7.3	91
18	Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiology, 2002, 31, 690-694.	2.0	89

#	Article	IF	Citations
19	Sodium 18F-Fluoride PET/CT of Bone, Joint, and Other Disorders. Seminars in Nuclear Medicine, 2015, 45, 58-65.	4.6	87
20	Appropriate Use Criteria for ¹⁸F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. Journal of Nuclear Medicine, 2017, 58, 2026-2037.	5.0	78
21	Molecular Imaging of Prostate Cancer with PET. Journal of Nuclear Medicine, 2013, 54, 1685-1688.	5.0	74
22	Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nature Reviews Urology, 2009, 6, 317-323.	3.8	73
23	Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. American Journal of Roentgenology, 2017, 209, 277-288.	2.2	68
24	[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. International Journal of Clinical Oncology, 2008, 13, 42-47.	2.2	67
25	Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. Molecular Imaging and Biology, 2018, 20, 501-509.	2.6	67
26	[F-18]Fluorodeoxyglucose Positron Emission Tomography and Positron Emission Tomography. Journal of Computer Assisted Tomography, 2007, 31, 223-228.	0.9	66
27	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. Journal of Nuclear Medicine, 2022, 63, 59-68.	5.0	61
28	Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 580-601.	1.0	55
29	Evaluation of Rare Tumors with [F-18]Fluorodeoxyglucose Positron Emission Tomography. Molecular Imaging and Biology, 1999, 2, 153-158.	0.3	53
30	Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies. PET Clinics, 2018, 13, 623-634.	3.0	47
31	FDG PET in Prostate Cancer. PET Clinics, 2009, 4, 155-161.	3.0	46
32	Targeted Î±-Particle Therapy of Bone Metastases in Prostate Cancer. Clinical Nuclear Medicine, 2013, 38, 966-971.	1.3	46
33	PSMA PET in Prostate Cancer. Journal of Nuclear Medicine, 2015, 56, 1131-1132.	5.0	46
34	The Effect of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography on the Management of Cutaneous Malignant Melanoma. Clinical Nuclear Medicine, 2000, 25, 48.	1.3	43
35	FDG PET in suspected recurrent and metastatic prostate cancer. Oncology Reports, 2003, 10, 1485-8.	2.6	43
36	Targeted Radionuclide Therapy: Practical Applications and Future Prospects. Biomarkers in Cancer, 2016, 8s2, BIC.S31804.	3.6	42

#	Article	IF	Citations
37	PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 25S-29S.	5.0	38
38	Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging. American Journal of Roentgenology, 2018, 210, W245-W263.	2.2	37
39	18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA â‰¥ 1 ng/mL After Definitive Primary Treatment. Clinical Nuclear Medicine, 2019, 44, e128-e132.	1.3	37
40	Musculoskeletal system. Seminars in Nuclear Medicine, 2004, 34, 254-261.	4.6	36
41	One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 195-199.	1.0	34
42	Low-count whole-body PET with deep learning in a multicenter and externally validated study. Npj Digital Medicine, 2021, 4, 127.	10.9	34
43	[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Annals of Nuclear Medicine, 2008, 22, 787-793.	2.2	33
44	Pharmacologic Interventions in Nuclear Radiology: Indications, Imaging Protocols, and Clinical Results. Radiographics, 2002, 22, 477-490.	3.3	32
45	Update on advances in molecular PET in urological oncology. Japanese Journal of Radiology, 2016, 34, 470-485.	2.4	31
46	PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin. PET Clinics, 2018, 13, 609-621.	3.0	31
47	Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 19S-24S.	5.0	30
48	Preservation of retinotopic map in retinal degeneration. Experimental Eye Research, 2012, 98, 88-96.	2.6	29
49	PET in pediatric diseases. Radiologic Clinics of North America, 2005, 43, 135-152.	1.8	28
50	Positron Emission Tomography in Prostate Cancer: Summary of Systematic Reviews and Meta-Analyses. Tomography, 2015, 1, 18-22.	1.8	28
51	A reusable perfusion supporting tissue-mimicking material for ultrasound hyperthermia phantoms. Medical Physics, 1990, 17, 380-390.	3.0	26
52	Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸F-FDG PET/CT. Journal of Nuclear Medicine, 2019, 60, 1524-1530.	5.0	25
53	Glucose metabolism of human prostate cancer mouse xenografts. Molecular Imaging, 2005, 4, 91-7.	1.4	25
54	SPECT and PET in the Evaluation of Coronary Artery Disease. Radiographics, 1999, 19, 915-926.	3.3	24

#	Article	IF	Citations
55	Evolving Cardiac Conduction Phenotypes in Developing Zebrafish Larvae: Implications to Drug Sensitivity. Zebrafish, 2010, 7, 325-331.	1.1	24
56	PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1803-1811.	2.5	24
57	Hepatocellular Carcinoma and Gastroenteropancreatic Neuroendocrine Tumors: Potential Role of Other Positron Emission Tomography Radiotracers. Seminars in Nuclear Medicine, 2012, 42, 247-254.	4.6	23
58	Effect of Atropine and Sincalide on the Intestinal Uptake of F-18 Fluorodeoxyglucose. Clinical Nuclear Medicine, 1999, 24, 965.	1.3	23
59	2-Deoxy-2-[F-18]Fluoro-d-Glucoseâ€"Positron Emission Tomography/Computed Tomography Imaging Evaluation of Esophageal Cancer. Molecular Imaging and Biology, 2006, 8, 193-200.	2.6	22
60	Molecular Imaging of Prostate Cancer: A Concise Synopsis. Molecular Imaging, 2009, 8, 7290.2009.00010.	1.4	22
61	The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate, 2010, 70, 1359-1370.	2.3	21
62	Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. Clinical Nuclear Medicine, 2018, 43, e226-e231.	1.3	20
63	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2300-2309.	6.4	20
64	Actinomycosis Mimicking Anastomotic Recurrent Esophageal Cancer on PET-CT. Clinical Nuclear Medicine, 2006, 31, 646-647.	1.3	19
65	FDG PET-CT Demonstration of Sjogren??s Sialoadenitis. Clinical Nuclear Medicine, 2005, 30, 698-699.	1.3	18
66	Targeted Î±-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 475-484.	1.0	17
67	Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hellenic Journal of Nuclear Medicine, 2009, 12, 26-9.	0.3	17
68	Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics, 2020, 10, 3254-3262.	10.0	15
69	Role of Imaging in Prostate Cancer. PET Clinics, 2009, 4, 135-138.	3.0	14
70	Association of Overall Survival with Glycolytic Activity of Castrate-Resistant Prostate Cancer Metastases. Radiology, 2015, 274, 624-625.	7.3	14
71	Science to Practice: Does FDG Differentiate Morphologically Unstable from Stable Atherosclerotic Plaque?. Radiology, 2017, 283, 1-3.	7.3	14
72	Management of Primary Osseous Spinal Tumors with PET. PET Clinics, 2019, 14, 91-101.	3.0	14

#	Article	IF	Citations
73	Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. Abdominal Radiology, 2016, 41, 889-898.	2.1	13
74	Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology. Journal of Nuclear Medicine, 2018, 59, 1338-1339.	5.0	13
75	Role of ¹⁸F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 216, 851-859.	2.2	13
76	FDG PET/CT Demonstration of Pancreatic Metastasis From Prostate Cancer. Clinical Nuclear Medicine, 2011, 36, 961-962.	1.3	12
77	[¹⁸ F]-2â€² -Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (¹⁸ F-FMAU) in Prostate Cancer: Initial Preclinical Observations. Molecular Imaging, 2012, 11, 7290.2012.00004.	1.4	12
78	Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with 18F-NaF PET/CT. Nuclear Medicine and Molecular Imaging, 2019, 53, 247-252.	1.0	12
79	Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and 18F-FMAU PET/CT. Clinical Nuclear Medicine, 2015, 40, e426-e428.	1.3	11
80	PSMA PET: Transformational Change in Prostate Cancer Management?. Journal of Nuclear Medicine, 2018, 59, 228-229.	5.0	11
81	The reproductive tract. Seminars in Nuclear Medicine, 2004, 34, 262-273.	4.6	10
82	American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. Journal of Nuclear Medicine, 2015, 56, 642-645.	5.0	10
83	¹⁸F-NaF/²²³RaCl₂ theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. British Journal of Radiology, 2018, 91, 20170948.	2.2	10
84	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. Journal of Nuclear Medicine, 2020, 61, 552-562.	5.0	10
85	The SNMMI and EANM Practice Guideline for Tele-Nuclear Medicine 2.0. Journal of Nuclear Medicine Technology, 2014, 42, 15-19.	0.8	9
86	Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors. Nuclear Medicine and Molecular Imaging, 2021, 55, 31-37.	1.0	9
87	Choline autoradiography of human prostate cancer xenograft: effect of castration. Molecular Imaging, 2008, 7, 147-52.	1.4	9
88	[18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations. Molecular Imaging, 2012, 11, 426-32.	1.4	9
89	Can Choline PET Tackle the Challenge of Imaging Prostate Cancer?. Theranostics, 2012, 2, 331-332.	10.0	8
90	ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. Journal of Nuclear Medicine, 2017, 58, 1174-1176.	5.0	8

#	Article	IF	Citations
91	Targeted Î±-therapy in non-prostate malignancies. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 47-53.	6.4	8
92	Prostate Cancer. Methods in Molecular Biology, 2011, 727, 265-290.	0.9	8
93	Molecular imaging of prostate cancer: a concise synopsis. Molecular Imaging, 2009, 8, 56-64.	1.4	8
94	Fusion Positron Emission Tomographyâ€“Computed Tomography Demonstration of Epidural Metastases. Clinical Nuclear Medicine, 2004, 29, 39-40.	1.3	7
95	Gallium-68â€“Labeled Prostate-Specific Membrane Antigenâ€“11 PET/CT of Prostate and Nonprostate Cancers. American Journal of Roentgenology, 2019, 213, 286-299.	2.2	7
96	Colonic FDG Uptake Pattern in Subjects Receiving Oral Contrast With No Known or Suspected Colonic Disease. Clinical Nuclear Medicine, 2011, 36, 754-756.	1.3	6
97	Imaging Cellular Proliferation in Prostate Cancer with Positron Emission Tomography. Asia Oceania Journal of Nuclear Medicine and Biology, 2015, 3, 72-6.	0.1	6
98	Procedure guideline for telenuclear medicine 1.0. Journal of Nuclear Medicine, 2002, 43, 1410-3.	5.0	6
99	Utility of a stimulus artifact suppressor for transesophageal pacing. American Journal of Cardiology, 1990, 65, 393-394.	1.6	5
100	ACRâ€“ASTRO Practice Guideline for the Performance of Therapy With Unsealed Radiopharmaceutical Sources. Clinical Nuclear Medicine, 2011, 36, e72-e80.	1.3	5
101	Prognostic Utility of PET in Prostate Cancer. PET Clinics, 2015, 10, 255-263.	3.0	5
102	Radiotheranostics in Prostate Cancer: Introduction and Overview. Journal of Nuclear Medicine, 2016, 57, 1S-2S.	5.0	5
103	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. Journal of Nuclear Medicine, 2022, 63, 1836-1843.	5.0	5
104	Adenocarcinoma in an Indiana Pouch on PET-CT. Clinical Nuclear Medicine, 2007, 32, 57-58.	1.3	4
105	Preclinical evaluation of a 64Cu-labeled disintegrin for PET imaging of prostate cancer. Amino Acids, 2019, 51, 1569-1575.	2.7	4
106	Value proposition of PSMA-targeted Î±â€“particle radioligand therapy in metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 8-10.	6.4	4
107	Prostate-specific antigen and prostate-specific antigen kinetics in predicting 18F-sodium fluoride positron emission tomography-computed tomography positivity forfirst bone metastases in patients with biochemical recurrence after radical prostatectomy. World Journal of Nuclear Medicine, 2017, 16, 229-236.	0.5	4
108	Duplex Doppler sonography: is there clinical relevance to elevated renal vein velocity in kidney transplants?. Clinical Imaging, 2016, 40, 1237-1245.	1.5	3

#	Article	IF	Citations
109	SNMMI Comment on the 2016 Society of Surgical Oncology â€œChoosing Wiselyâ€•Recommendation on the Use of PET/CT in Colorectal Cancer. Journal of Nuclear Medicine, 2017, 58, 11-12.	5.0	3
110	Highlights of articles published in annals of nuclear medicine 2016. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1928-1933.	6.4	3
111	The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity. Diagnostics, 2017, 7, 43.	2.6	3
112	Incidental Detection of Meningioma by 18F-FMAU PET/CT in a Patient With Suspected Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, e245-e246.	1.3	3
113	Point: The Existential Threat to NuclearÂMedicine. Journal of the American College of Radiology, 2018, 15, 384-386.	1.8	3
114	A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy. Canadian Urological Association Journal, 2019, 14, 130-138.	0.6	3
115	Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences. Clinical Nuclear Medicine, 2020, 45, 668-671.	1.3	3
116	Competitive Advantage of PSMA Theranostics in Prostate Cancer. Radiology, 2021, 299, 261-263.	7.3	3
117	SNMMI Leadership Update: Developing Evidence-Based Appropriate Use Criteria under the Protecting Access to Medicare Act of 2014. Journal of Nuclear Medicine, 2015, 56, 20N.	5.0	3
118	â€œAlas, Poor Yorick!â€• American Journal of Roentgenology, 2002, 178, 178-178.	2.2	2
119	SNMMI Comment on ASCO 2013 â€œChoosing Wiselyâ€•Recommendation on Use of PET/CT in Recurrent Cancer Surveillance. Journal of Nuclear Medicine, 2014, 55, 699-700.	5.0	2
120	Multimodal imaging in focal therapy planning and assessment in primary prostate cancer. Clinical and Translational Imaging, 2017, 5, 199-208.	2.1	2
121	Management Impact of Metachronous Oligometastatic Disease Identified on 18F-Fluciclovine (Axuminâ„¢) PET/CT in Biochemically Recurrent Prostate Cancer. Molecular Imaging and Biology, 2022, 24, 920-927.	2.6	2
122	Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer. PET Clinics, 2022, 17, 389-397.	3.0	2
123	Death Valley, California. American Journal of Roentgenology, 2002, 179, 1244-1244.	2.2	1
124	Advances in Imaging of Nonthyroid Endocrine Neoplasms. Problems in General Surgery, 2003, 20, 11-20.	0.2	1
125	Invited Commentary: Nuclear Theranosticsâ€”The Path Forward. Radiographics, 2020, 40, 1741-1742.	3.3	1
126	Effect of Androgen on Normal Biodistribution of [18F]-2â€™-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. Anticancer Research, 2017, 37, 475-480.	1.1	1

#	Article	IF	Citations
127	SNMMI/ACR/ASNC/SCMR joint credentialing statement for cardiac PET/MRI. Journal of Cardiovascular Magnetic Resonance, 2022, 24, .	3.3	1
128	Gone Fishing. American Journal of Roentgenology, 2000, 175, 140-140.	2.2	0
129	Room with a View (North Coast of Aruba). American Journal of Roentgenology, 2001, 177, 806-806.	2.2	0
130	Raw and Ripe. American Journal of Roentgenology, 2001, 177, 886-886.	2.2	0
131	Joshua Tree National Park, California. American Journal of Roentgenology, 2002, 178, 110-110.	2.2	0
132	Yosemite, California. American Journal of Roentgenology, 2003, 181, 302-302.	2.2	0
133	Cancun, Mexico. American Journal of Roentgenology, 2003, 181, 1092-1092.	2.2	0
134	Preface. PET Clinics, 2009, 4, ix.	3.0	0
135	Influence of Trigger PSA and PSA Kinetics on ¹¹C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy. Journal of Nuclear Medicine, 2010, 51, 498.2-499.	5.0	0
136	Reply: Staging, Restaging, and Treatment Response Assessment in Lymphomas: What We Should Know. Journal of Nuclear Medicine, 2018, 59, 715-716.	5.0	0
137	Single Institution Patterns of Management of (18)F-Fluciclovine-detected Prostate Cancer Recurrences. International Journal of Radiation Oncology Biology Physics, 2020, 108, E62-E63.	0.8	0
138	Imaging of Glycolysis with 18F-FDG PET. , 2017, , 87-94.		0
139	Editorial Comment. Journal of Urology, 2019, 202, 420-421.	0.4	0
140	Prostate Cancer Lymphangitic Pulmonary Carcinomatosis. Clinical Nuclear Medicine, 2020, 45, 727-729.	1.3	0
141	Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer. Radiology, 0, , .	7.3	0